Y-mAbs Therapeutics (YMAB) Short Interest Ratio & Short Volume $4.30 +0.05 (+1.06%) As of 07/3/2025 02:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Short Interest Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock Y-mAbs Therapeutics Short Interest DataY-mAbs Therapeutics (YMAB) has a short interest of 2.65 million shares, representing 7.79% of the float (the number of shares available for trading by the public). This marks a -1.49% decrease in short interest from the previous month. The short interest ratio (days to cover) is 11.2, indicating that it would take 11.2 days of the average trading volume of 298,167 shares to cover all short positions.Current Short Interest2,650,000 sharesPrevious Short Interest2,690,000 sharesChange Vs. Previous Month-1.49%Dollar Volume Sold Short$12.48 millionShort Interest Ratio11.2 Days to CoverLast Record DateJune 15, 2025Outstanding Shares45,280,000 sharesFloat Size34,020,000 sharesShort Percent of Float7.79%Today's Trading Volume81,293 sharesAverage Trading Volume298,167 sharesToday's Volume Vs. Average27% Short Selling Y-mAbs Therapeutics? Sign up to receive the latest short interest report for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartYMAB Short Interest Over TimeYMAB Days to Cover Over TimeYMAB Percentage of Float Shorted Over Time Y-mAbs Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 6/15/20252,650,000 shares $12.48 million -1.5%7.8%11.2 $4.71 5/31/20252,690,000 shares $12.67 million -5.3%7.9%10.8 $4.71 5/15/20252,840,000 shares $10.96 million -8.1%8.3%10 $3.86 4/30/20253,090,000 shares $13.13 million +0.7%9.0%8.8 $4.25 4/15/20253,070,000 shares $16.42 million -16.1%8.9%7.7 $5.35 3/31/20253,660,000 shares $16.21 million -17.6%10.6%8.6 $4.43 3/15/20254,440,000 shares $20.73 million -6.1%12.9%9.9 $4.67 2/28/20254,730,000 shares $26.28 million +5.4%13.7%10.7 $5.56 2/15/20254,490,000 shares $28.02 million +11.4%13.2%11 $6.24 1/31/20254,030,000 shares $24.06 million +7.8%10.9%10.3 $5.97 Get the Latest News and Ratings for YMAB and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Y-mAbs Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 1/15/20253,740,000 shares $23.90 million +5.1%10.1%11.2 $6.39 12/31/20243,560,000 shares $27.87 million -1.7%9.6%12.5 $7.83 12/15/20243,620,000 shares $34.14 million -5.7%9.7%14.6 $9.43 11/30/20243,840,000 shares $45.77 million +5.8%10.3%15.9 $11.92 11/15/20243,630,000 shares $40.44 million -9.5%9.8%14 $11.14 10/31/20244,010,000 shares $58.19 million -5.7%10.8%15 $14.51 10/15/20244,250,000 shares $60.78 million +1.9%11.5%16.8 $14.30 9/30/20244,170,000 shares $54.84 million +3.5%11.3%16 $13.15 9/15/20244,030,000 shares $55.37 million -3.8%10.9%13.9 $13.74 8/31/20244,190,000 shares $59.96 million -12.7%11.4%15 $14.31 8/15/20244,800,000 shares $58.61 million +3.0%13.0%16.9 $12.21 7/31/20244,660,000 shares $57.22 million +9.9%12.9%14.8 $12.28 7/15/20244,240,000 shares $55.04 million +18.1%11.7%12.5 $12.98 6/30/20243,590,000 shares $43.37 million -1.9%9.9%10.1 $12.08 6/15/20243,660,000 shares $43.59 million +7.3%10.1%10.5 $11.91 5/31/20243,410,000 shares $41.26 million -10.0%9.4%9.3 $12.10 5/15/20243,790,000 shares $46.16 million +52.8%9.9%10.3 $12.18 4/30/20242,480,000 shares $37.72 million +6.4%7.5%6.3 $15.21 4/15/20242,330,000 shares $34.74 million +4.0%7.0%5.9 $14.91 3/31/20242,240,000 shares $36.42 million +6.7%6.8%5.3 $16.26 3/15/20242,100,000 shares $30.87 million -3.2%6.4%5.3 $14.70 2/29/20242,170,000 shares $36.24 million -1.4%6.6%5.6 $16.70 2/15/20242,200,000 shares $35.20 million -2.2%6.7%6.2 $16.00 1/31/20242,250,000 shares $28.78 million +5.6%6.8%7.3 $12.79 1/15/20242,130,000 shares $20.55 million -7.8%6.4%8.3 $9.65 12/31/20232,310,000 shares $15.75 million +6.9%6.9%11.3 $6.82 12/15/20232,160,000 shares $14.32 million -13.3%6.5%10.6 $6.63 11/30/20232,490,000 shares $15.46 million -2.4%7.4%13.7 $6.21 11/15/20232,550,000 shares $13.39 million +2.0%7.6%14.9 $5.25 10/31/20232,500,000 shares $13.35 million -4.2%7.6%13.7 $5.34Have you heard of “E.I.”? (Ad)Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing to invest in new "E.I." Tech, which one expert estimates will grow by 200,000%. Becoming bigger than the automobile, PC, and cell phone markets... COMBINED!There are 3 simple steps investors can take to be early to this 200,000% E.I. boom - if they act fas 10/15/20232,610,000 shares $13.83 million -2.6%7.9%13.6 $5.30 9/30/20232,680,000 shares $14.61 million -2.9%8.1%14.9 $5.45 9/15/20232,760,000 shares $13.77 million +6.2%8.4%14.6 $4.99 8/31/20232,600,000 shares $13.18 million -17.2%7.9%11.9 $5.07 8/15/20233,140,000 shares $17.90 million +52.4%9.5%12.8 $5.70 7/31/20232,060,000 shares $12.55 million +6.7%6.1%7 $6.09 7/15/20231,930,000 shares $13.68 million +7.2%5.8%6.3 $7.09 6/30/20231,800,000 shares $12.22 million +2.3%5.5%5.1 $6.79 6/15/20231,760,000 shares $14.10 million +6.7%5.3%2.4 $8.01 5/31/20231,650,000 shares $13.41 million -8.3%5.0%2.3 $8.13 5/15/20231,800,000 shares $18.50 million -2.7%5.5%2.4 $10.28 4/30/20231,850,000 shares $11.08 million +3.4%5.6%2.6 $5.99 4/15/20231,790,000 shares $11.71 million -28.4%5.4%2.6 $6.54 3/31/20232,500,000 shares $12.53 million +26.9%7.6%3.7 $5.01 3/15/20231,970,000 shares $6.64 million +10.7%5.6%6.3 $3.37 2/28/20231,780,000 shares $6.76 million -3.3%5.0%4.7 $3.80 2/15/20231,840,000 shares $7.91 million -5.2%5.2%4.7 $4.30 1/31/20231,940,000 shares $8.71 million +1.0%5.5%4 $4.49 1/15/20231,920,000 shares $9.16 million -0.5%5.5%2.8 $4.77 12/30/20221,930,000 shares $9.42 million +14.2%5.5%2.8 $4.88 12/15/20221,690,000 shares $8.75 million -1.7%4.8%2.4 $5.18 11/30/20221,720,000 shares $7.69 million +17.0%4.9%2.7 $4.47 11/15/20221,470,000 shares $6.56 million -52.3%4.2%2.4 $4.46 10/31/20223,080,000 shares $11.12 million -17.0%8.7%5.8 $3.61 10/15/20223,710,000 shares $53.50 million -1.6%10.5%13.5 $14.42 9/30/20223,770,000 shares $54.36 million -2.3%10.7%13.5 $14.42 9/15/20223,860,000 shares $55.97 million +2.1%10.9%13.6 $14.50 8/31/20223,780,000 shares $60.78 million +1.1%10.7%11.5 $16.08 8/15/20223,740,000 shares $70.39 million +5.4%10.6%10.5 $18.82 7/31/20223,550,000 shares $55.34 million +2.9%10.1%8.3 $15.59 7/15/20223,450,000 shares $57.41 million -4.7%9.8%7.3 $16.64 6/30/20223,620,000 shares $54.77 million -9.7%10.3%7.6 $15.13 6/15/20224,010,000 shares $46.36 million -4.3%11.4%8.8 $11.56 5/31/20224,190,000 shares $52.12 million +1.2%11.9%9 $12.44 5/15/20224,140,000 shares $42.64 million +43.3%11.8%8.6 $10.30 4/30/20222,890,000 shares $24.28 million -1.7%8.2%3.9 $8.40 4/15/20222,940,000 shares $37.69 million +3.9%8.4%3.9 $12.82 3/31/20222,830,000 shares $33.62 million +25.2%8.1%3.7 $11.88 3/15/20222,260,000 shares $19.66 million -5.8%6.4%3 $8.70 2/28/20222,400,000 shares $21.86 million -6.6%6.8%3.4 $9.11 2/15/20222,570,000 shares $20.82 million +31.1%7.3%3.7 $8.10 1/31/20221,960,000 shares $19.38 million No Change5.7%5 $9.89 1/15/20221,960,000 shares $23.76 million +2.1%5.7%6.8 $12.12 12/31/20211,920,000 shares $31.12 million -6.8%5.6%8.5 $16.21 12/15/20212,060,000 shares $34.20 million -7.2%6.0%9.6 $16.60 11/30/20212,220,000 shares $37.92 million -7.9%6.5%11.4 $17.08 11/15/20212,410,000 shares $52.78 million -9.1%7.0%13.2 $21.90 10/29/20212,650,000 shares $65.08 million +7.7%7.7%14.3 $24.56 10/15/20212,460,000 shares $65.63 million +1.2%7.2%13.2 $26.68 9/30/20212,430,000 shares $69.35 million -10.3%7.1%11.8 $28.54Have you heard of “E.I.”? (Ad)Inside Expert: New "E.I." Tech Could Be Poised For 200,000% Growth Meta, Apple, and even NASA are rushing to invest in new "E.I." Tech, which one expert estimates will grow by 200,000%. Becoming bigger than the automobile, PC, and cell phone markets... COMBINED!There are 3 simple steps investors can take to be early to this 200,000% E.I. boom - if they act fas 9/15/20212,710,000 shares $91.73 million +2.3%7.9%12.6 $33.85 8/31/20212,650,000 shares $81.57 million -12.0%7.7%11.1 $30.78 8/13/20213,010,000 shares $87.56 million +2.7%8.8%11.9 $29.09 7/30/20212,930,000 shares $96.98 million +4.3%8.5%11.4 $33.10 7/15/20212,810,000 shares $87.59 million -1.8%8.2%10.8 $31.17 6/30/20212,860,000 shares $96.67 million -4.4%8.4%10.6 $33.80 6/15/20212,990,000 shares $103.39 million -4.5%8.8%10.3 $34.58 5/28/20213,130,000 shares $112.15 million -3.1%9.3%10.6 $35.83 5/14/20213,230,000 shares $105.78 million +7.7%9.6%10.1 $32.75 4/30/20213,000,000 shares $89.07 million -1.6%8.9%8.9 $29.69 4/15/20213,050,000 shares $81.71 million -15.8%10.8%9.7 $26.79 3/31/20213,620,000 shares $107.08 million +27.9%12.8%11.8 $29.58 3/15/20212,830,000 shares $101.94 million -2.4%10.0%9.7 $36.02 2/26/20212,900,000 shares $97.67 million +30.0%10.7%10.9 $33.68 2/12/20212,230,000 shares $106.77 million -24.2%8.3%8.9 $47.88 1/29/20212,940,000 shares $125.30 million -2.7%11.7%13.2 $42.62 1/15/20213,020,000 shares $150.94 million -1.6%12.0%13.8 $49.98 12/31/20203,070,000 shares $153.53 million -12.5%12.2%15.3 $50.01 12/15/20203,510,000 shares $183.19 million +0.3%13.9%17.1 $52.19 11/30/20203,500,000 shares $168.67 million +1.7%14.0%19.1 $48.19 10/30/20203,350,000 shares $145.26 million +2.8%13.4%23 $43.36 10/15/20203,260,000 shares $129.85 million +11.6%13.2%21.6 $39.83 9/30/20202,920,000 shares $112.10 million +15.4%11.9%18.2 $38.39 9/15/20202,530,000 shares $99.61 million -0.4%10.3%14.6 $39.37 8/31/20202,540,000 shares $109.30 million -4.2%10.3%13.7 $43.03 8/14/20202,650,000 shares $103.38 million -0.8%10.8%12.2 $39.01 7/31/20202,670,000 shares $93.80 million +3.9%10.9%10.7 $35.13 7/15/20202,570,000 shares $102.34 million +2.4%10.6%10.3 $39.82 YMAB Short Interest - Frequently Asked Questions What is Y-mAbs Therapeutics' current short interest? Short interest is the volume of Y-mAbs Therapeutics shares that have been sold short but have not yet been covered or closed out. As of June 15th, investors have sold 2,650,000 shares of YMAB short. 7.79% of Y-mAbs Therapeutics' shares are currently sold short. Learn More on Y-mAbs Therapeutics' current short interest. What is a good short interest ratio for Y-mAbs Therapeutics? The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. YMAB shares currently have a short interest ratio of 11.0. Learn More on Y-mAbs Therapeutics's short interest ratio. What is a good short interest percentage for Y-mAbs Therapeutics? Companies that have a short interest as a percentage of float below 10% indicates positive investor sentiment and few short sellers. Stocks with a short interest percentage above 10% is considered high, suggesting some investors are pessimistic about the stock. Companies with a short interest percentage of 20% or more indicates widespread negative sentiment. 7.79% of Y-mAbs Therapeutics' floating shares are currently sold short. Is Y-mAbs Therapeutics' short interest increasing or decreasing? Y-mAbs Therapeutics saw a decline in short interest during the month of June. As of June 15th, there was short interest totaling 2,650,000 shares, a decline of 1.5% from the previous total of 2,690,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. What is Y-mAbs Therapeutics' float size? Y-mAbs Therapeutics currently has issued a total of 45,280,000 shares. Some of Y-mAbs Therapeutics' outstanding shares are available for trading, while others are subject to various restrictions. The public float, also referred to as floating shares or "the float", are shares that publicly owned, unrestricted and available to trade on the open market. Y-mAbs Therapeutics currently has a public float of 34,020,000 shares. How does Y-mAbs Therapeutics' short interest compare to its competitors? 7.79% of Y-mAbs Therapeutics' shares are currently sold short. Here is how the short interest of companies in the industry of "pharmaceutical products" compare to Y-mAbs Therapeutics: Oric Pharmaceuticals, Inc. (16.01%), Praxis Precision Medicines, Inc. (9.55%), Cogent Biosciences, Inc. (15.65%), Chimerix, Inc. (4.27%), Avid Bioservices, Inc. (18.17%), Anavex Life Sciences Corp. (33.33%), Syndax Pharmaceuticals, Inc. (26.66%), ArriVent BioPharma, Inc. (25.85%), uniQure N.V. (14.71%), Immunome, Inc. (16.30%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: SPDR S&P 500 ETF Trust ($69.26 billion), Invesco QQQ ($25.22 billion), iShares Russell 2000 ETF ($20.33 billion), iShares 20+ Year Treasury Bond ETF ($9.99 billion), MicroStrategy Incorporated ($9.12 billion), Canadian Natural Resources Limited ($6.73 billion), SPDR S&P Biotech ETF ($6.52 billion), Invesco S&P 500 Equal Weight ETF ($5.60 billion), Financial Select Sector SPDR Fund ($4.64 billion), and iShares iBoxx $ Investment Grade Corporate Bond ETF ($4.59 billion). View all of the most shorted stocks. What does it mean to sell short Y-mAbs Therapeutics stock? Short selling YMAB is an investing strategy that aims to generate trading profit from Y-mAbs Therapeutics as its price is falling. YMAB shares are trading up $0.05 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Y-mAbs Therapeutics? A short squeeze for Y-mAbs Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of YMAB, which in turn drives the price of the stock up even further. How often is Y-mAbs Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including YMAB, twice per month. The most recent reporting period available is June, 15 2025. More Short Interest Resources from MarketBeat Related Companies Oric Pharmaceuticals Short Interest Data Praxis Precision Medicines Short Interest Data Cogent Biosciences Short Interest Data Chimerix Short Interest Data Avid Bioservices Short Interest Data Anavex Life Sciences Short Interest Data Syndax Pharmaceuticals Short Interest Data ArriVent BioPharma Short Interest Data uniQure Short Interest Data Immunome Short Interest Data Short Interest Tools Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:YMAB) was last updated on 7/4/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredElon just did WHAT!?As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...Brownstone Research | SponsoredCrypto Is Pumping Again – Now Comes the Real OpportunityThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredGold: Now legal tender in many statesThe perfect gold play right now? (currently under $10) Everything in the news now lines up perfectly for an...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Y-mAbs Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Y-mAbs Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free YMAB Stock Alerts